Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress
· The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF) · Interim data have shown stabilization of the disease and an increase in lung capacity at 24 and 36 weeks · Oral presentation by Professor Toby Maher on September 4 at 15:00 CET Gothenburg, August 17, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces that the previously published interim data from AIR, a phase 2 trial in IPF), will be